Clément Larrue
Reproducibility track record
1
assessed papers
32/100
mean reproducibility
0
reproduced (C1–C2)
1
flagged
0
total citations
flag rate:
100%
(1/1)
The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.
Authorship role
first author: 0
last author: 0
Topics
Funders
—
Frequent co-authors
Guilhem Clary 1Elissa Khadra 1Didier Bouscary 1Justine Decroocq 1Charles Dussiau 1Morgane Le Gall 1Michaëla Fontenay 1Nicolas Chapuis 1Zubaidan Tuerdi 1Françoise Levavasseur 1
Institutions
Centre National de la Recherche Scientifique 1Inserm 1Université Paris Cité 1Institut Cochin 1Acute Leukemia French Association 1Fondation pour la Recherche Médicale 1
Geography (author institutions)
FR 1DE 1CH 1
Co-author network
Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.
How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.
Assessed papers (1)
Complete publication record (314)
Request a reproduction →1 assessed by us (0 reproduced) · 313 not yet assessed — every PubMed paper on record, linked below.
-
Targeting ferritinophagy to iron out <i>Tet2</i>-mutant cells ↗Blood · 2025 · PMID 40906503not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Integrated analysis of post-transcriptional regulations reveals insights into acute myeloid leukemia⚑Communications Biology · 2025 · PMID 41407883L1 32/100 ⚑
-
Selective haematological cancer eradication with preserved haematopoiesis ↗Nature · 2024 · PMID 38778101not yet assessed
-
Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models ↗Science Translational Medicine · 2024 · PMID 39047119not yet assessed
-
The E3 ubiquitin ligase MARCH5 promotes mitochondrial fusion and cell-cycle progression in acute myeloid leukemia ↗Blood Advances · 2024 · PMID 39471482not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in <i>FLT3</i> -Mutant Leukemia ↗Cancer Discovery · 2023 · PMID 37012202not yet assessed
-
CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia ↗Cancer Research · 2023 · PMID 37327406not yet assessed
-
Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia ↗Leukemia · 2023 · PMID 36739349not yet assessed
-
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy ↗The Journal of Experimental Medicine · 2023 · PMID 37773046not yet assessed
-
Very short insertions in the <i>FLT3</i> gene are of therapeutic significance in acute myeloid leukemia ↗Blood Advances · 2023 · PMID 37987760not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Epitope Engineered Human Haematopoietic Stem Cells are Shielded from CD123-targeted Immunotherapy ↗bioRxiv (Cold Spring Harbor Laboratory) · 2023not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells ↗bioRxiv (Cold Spring Harbor Laboratory) · 2023not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia ↗Cell Reports · 2022 · PMID 34986346not yet assessed
-
C/EBPα confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress in FLT3-mutant leukemia ↗bioRxiv (Cold Spring Harbor Laboratory) · 2022not yet assessed
-
Mitochondrial Fusion Supports Proliferation of Leukemia-Initiating Cells Through mTORC1 in Patient-Derived Xenograft Models ↗SSRN Electronic Journal · 2022not yet assessed
-
not yet assessed
-
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia ↗Haematologica · 2021 · PMID 33406814not yet assessed
-
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia ↗The Journal of Experimental Medicine · 2021 · PMID 33760042not yet assessed
-
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia ↗Nature Cancer · 2021 · PMID 35122057not yet assessed
-
Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells ↗Nature Communications · 2021 · PMID 33462236not yet assessed
-
AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia ↗Cancers · 2021 · PMID 34885077not yet assessed
-
not yet assessed
-
Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites ↗Nature Communications · 2020 · PMID 32792483not yet assessed
-
Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia ↗Cancer Discovery · 2020 · PMID 32641297not yet assessed
-
Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo ↗Cancers · 2020 · PMID 32610562not yet assessed
-
Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia ↗FEBS Open Bio · 2020 · PMID 33410599not yet assessed
-
An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML ↗bioRxiv (Cold Spring Harbor Laboratory) · 2020not yet assessed
-
Adrenomedullin-CALCRL Axis Controls Relapse-Initiating Drug Tolerant Acute Myeloid Leukemia Cells ↗bioRxiv (Cold Spring Harbor Laboratory) · 2020not yet assessed
-
Mitochondrial determinants of response and resistance to venetoclax <i>plus</i> cytarabine duplet therapy in acute myeloid leukemia ↗bioRxiv (Cold Spring Harbor Laboratory) · 2020not yet assessed
-
Adrenomedullin-CALCRL Axis Controls Relapse-Initiating Drug Tolerant Acute Myeloid Leukemia Cells ↗Research Square · 2020not yet assessed
-
Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia ↗Cancer Research · 2019 · PMID 31358527not yet assessed
-
Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia ↗Oncogenesis · 2019 · PMID 31311917not yet assessed
-
Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia ↗bioRxiv (Cold Spring Harbor Laboratory) · 2019not yet assessed
-
Combinatory therapy targeting mitochondrial oxidative phosphorylation improves efficacy of IDH mutant inhibitors in acute myeloid leukemia ↗bioRxiv (Cold Spring Harbor Laboratory) · 2019not yet assessed
-
Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia ↗European Journal Of Haematology · 2018 · PMID 30325535not yet assessed
-
Dexamethasone in hyperleukocytic acute myeloid leukemia ↗Haematologica · 2018 · PMID 29519869not yet assessed
-
Adrenomedullin Receptor Calcrl Drives Drug Resistance of Leukemic Stem Cells in Acute Myeloid Leukemia ↗Blood · 2018not yet assessed
-
IDH1 Mutation Enhances Catabolic Flexibility and Mitochondrial Dependencies to Favor Drug Resistance in Acute Myeloid Leukemia ↗SSRN Electronic Journal · 2018not yet assessed
-
Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism ↗Cancer Discovery · 2017 · PMID 28416471not yet assessed
-
Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia ↗Oncogene · 2017 · PMID 29059168not yet assessed
-
Dendrogenin A drives LXR to trigger lethal autophagy in cancers ↗Nature Communications · 2017 · PMID 29199269not yet assessed
-
RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia ↗Leukemia · 2017 · PMID 28914261not yet assessed
-
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia ↗The Journal of Experimental Medicine · 2016 · PMID 26951332not yet assessed
-
CHK1 as a therapeutic target to bypass chemoresistance in AML ↗Science Signaling · 2016 · PMID 27625304not yet assessed
-
Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia ↗Blood · 2016not yet assessed
-
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition ↗Blood · 2015 · PMID 26186940not yet assessed
-
Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells ↗Blood · 2015 · PMID 26286850not yet assessed
-
A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia ↗Blood Cancer Journal · 2015 · PMID 25794133not yet assessed
-
Antileukemic Activity of 2-Deoxy- <scp>d</scp> -Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with <i>FLT3-ITD</i> or <i>c-KIT</i> Mutations ↗Molecular Cancer Therapeutics · 2015 · PMID 26206337not yet assessed
-
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia ↗Oncotarget · 2015 · PMID 26515730not yet assessed
-
The Combination of ATRA and Dasatinib for Differentiation Therapy in Acute Myeloid Leukemias with IDH Mutations ↗Blood · 2015not yet assessed
-
Régulation de l'expression protéique des récepteurs à activité tyrosine kinase FLT3 et KIT dans les leucémies aigües myéloïdesThèses en ligne de l'Université Toulouse III (Université Toulouse III) · 2015not yet assessed
-
Regulation of FLT3 and KIT protein expression in acute myeloid leukemiatheses.fr (ABES) · 2015not yet assessed
-
not yet assessed
-
Abstract 5482: Antileukemic activity of 2-deoxy-d-glucose in acute myeloid leukemia ↗Cancer Research · 2014not yet assessed
-
Abstract 1336: Bortezomib induces the degradation of FLT3-ITD tyrosine kinase in acute myeloid leukemia through an autophagy-dependent mechanism ↗Cancer Research · 2014not yet assessed
-
Dendrogenin_A : A Natural Liver X Receptor Modulator for the Treatment of Acute Myeloid Leukemia ↗Blood · 2014not yet assessed
-
The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors ↗Leukemia · 2012 · PMID 22902361not yet assessed
-
Measurement of infarct size through serum myosin levels or imaging, thank to monoclonal antibodies ↗Journal of Molecular and Cellular Cardiology · 1986not yet assessed
Full bibliography from OpenAlex; reproducibility verdicts matched by PMID.
Author attribution follows OpenAlex disambiguation, which is imperfect — a researcher's papers can be split across profiles or mixed with a namesake.
Merged across profiles sharing this ORCID where present. See every “Larrue C” paper on PubMed ↗